Yellow fever primary prevention: Difference between revisions

Jump to navigation Jump to search
Line 19: Line 19:
{| style="border: 0px; font-size: 85%; margin: 3px; width:600px;" align=center
{| style="border: 0px; font-size: 85%; margin: 3px; width:600px;" align=center
|valign=top|
|valign=top|
|+'''Contraindications and precautions to yellow fever vaccine administration'''
|+
!style="background: #4479BA; color:#FFF;  width: 300px;" | Contraindications  
!style="background: #4479BA; color:#FFF;  width: 300px;" | Contraindications  
! style="background: #4479BA; color:#FFF;  width: 300px;" | Precautions
! style="background: #4479BA; color:#FFF;  width: 300px;" | Precautions

Revision as of 20:21, 22 December 2014

Yellow fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Yellow Fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Future or Investigational Therapies

Treatment

Case #1

Yellow fever primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Yellow fever primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Yellow fever primary prevention

CDC on Yellow fever primary prevention

Yellow fever primary prevention in the news

Blogs on Yellow fever primary prevention

Directions to Hospitals Treating Yellow fever

Risk calculators and risk factors for Yellow fever primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Primary Prevention

Vaccination

In 1937 Max Theiler working at the Rockefeller Foundation developed a vaccine for yellow fever that gives a ten-year or more immunity from the disease and effectively protects people traveling to affected areas, while at the same time being a means to control the disease. Woodcutters working in tropical areas should be particularly targeted for vaccination. Insecticides, protective clothing, and screening of houses are helpful but not always sufficient for mosquito control; people should always use an insecticide spray while in certain areas. In affected areas mosquito control methods have proven effective in decreasing the number of cases.[1] Recent studies have noted the increase in the number of areas affected by mosquito-borne viral infections and have called for further research and funding for vaccines.[2],[3]

Indications

  • Persons 9 months of age or older traveling to or living in a country that requires yellow fever vaccination for certain travelers. Check with your health-care provider.
  • Persons 9 months of age or older traveling to a country that does not require yellow fever vaccination but is located in an area where the risk of yellow fever is known to exist. Check with your health-care provider.

If you continue to live or travel in yellow fever-endemic areas, you should receive a booster dose of yellow fever vaccine after 10 years. Yellow fever vaccine may be given at the same time as most other vaccines.

Contraindications and Precautions for Vaccination

Contraindications Precautions
  • Allergy to vaccine component
  • Age <6 months
  • Symptomatic HIV infection or CD4 T-lymphocytes <200/mm3 (or <15% of total in children aged <6 years)1
  • Thymus disorder associated with abnormal immune-cell function
  • Primary immunodeficiencies
  • Malignant neoplasms
  • Transplantation
  • Immunosuppressive and immunomodulatory therapies
  • Age 6–8 months
  • Age ≥60 years
  • Asymptomatic HIV infection and CD4 T-lymphocytes 200–499/mm3 (or 15%–24% of total in children aged <6 years)1
  • Pregnancy
  • Breastfeeding

Risks of Vaccine

A vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of a vaccine causing serious harm, or death, is extremely small. Reactions are less likely to occur after a booster dose of yellow fever vaccine than after the first dose.

Mild Problems
  • soreness, redness, or swelling where the shot was given
  • fever
  • aches
  • If these problems occur, they usually begin soon after the shot and last for 5-10 days. In studies, they occurred in as many as 25% of vaccine recipients.
Severe Problems
  • Life-threatening allergic reaction (approximately 1 reported per 131,000 doses).
  • Severe nervous system reactions (approximately 1 reported per 150,000-250,000 doses).
  • Life-threatening severe illness with major organ system failure (approximately 1 reported per 200,000-300,000 doses, or 1 reported per 40,000-50,000 doses in people 60 years of age and older). More than half of the people who suffer these side effects die.
Moderate or Severe reaction
  • Look for any unusual condition, such as a high fever, behavior changes, or flu-like symptoms that occur 1-30 days after vaccination. Signs of an allergic reaction can include difficulty breathing, hoarseness or wheezing, hives, paleness, weakness, a fast heartbeat, or dizziness within a few minutes to a few hours after the shot.
  • Call a doctor, or get the person to a doctor right away.
  • Tell your doctor what happened, the date and time it happened, and when the vaccination was given.
  • Ask your health care provider to file a Vaccine Adverse Event Reporting System (VAERS) form if you have any reaction to the vaccine. Or call VAERS yourself at 1-800-822-7967, or visit their website at http://vaers.hhs.gov.

The National Vaccine Injury Compensation Program

In the rare event that you or your child has a serious reaction to a vaccine, a federal program has been created to help pay for the care of those who have been harmed. For details about the National Vaccine Injury Compensation Program, call 1-800-338-2382 or visit the program's website at http://www.hrsa.gov/vaccinecompensation.

References

  1. "Joint Statement on Mosquito Control in the United States from the U.S. Environmental Protection Agency (EPA) and the U.S. Centers for Disease Control and Prevention (CDC)" (PDF). Environmental Protection Agency. 2000-05-03. Unknown parameter |accessmonthday= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  2. Pugachev KV, Guirakhoo F, Monath TP (2005). "New developments in flavivirus vaccines with special attention to yellow fever". Curr Opin Infect Dis. 18 (5): 387–94. PMID 16148524.
  3. Petersen LR, Marfin AA (2005). "Shifting epidemiology of Flaviviridae". J Travel Med. 12 Suppl 1: S3–11. PMID 16225801.


Template:WikiDoc Sources